Pharmaceutical, healthcare and academic labs, research facilities and treatment centers face more threats than ever before. Valuable Biological Material (VBM) can be targeted by competitors, terrorists or even disgruntled employees. Safety issues can threaten employees, reputations and funding. Competitors and activists can target intellectual property. Inspectors can shut down operations and levy significant fines.
Mitigating these threats calls for a proactive biosecurity and biosafety program that anticipates and eliminates potential threats.
AT-RISK is the only company in North America that combines scientific and security expertise to provide comprehensive biosecurity and biosafety protection for commercial, academic and government labs, from Biological Safety Levels (BSL) 1-4.
By understanding biosecurity and biosafety at the pathogen level, AT-RISK can provide comprehensive security and safety solutions, including:
Biosecurity risk and threat assessments. This in-depth analysis evaluates threats (biosecurity), risks (biosafety) and vulnerabilities (biosecurity and biosafety) for labs and other biomedical facilities. Our experts review all aspects of your operation, from physical security and access control to operational procedures and pathogen-level safety. This assessment not only increases awareness, but also involves key stakeholders, including general counsel, the CFO and others.
Lab design consulting and support. We work with your design and construction team to create a facility that meets all guidelines for physical and operational security. From conceptual planning, through detailed design, construction and commissioning, we provide expert counsel to help clients monitor and control how materials, people, waste and research animals enter and leave the laboratory space.
Information infrastructure and compliance consulting. We design or fortify site-specific biosecurity and biosafety programs and IT infrastructure to protect operations and intellectual property from competitors, hackers, terrorists and others. We also design and implement compliance strategies based on government standards and agency guidelines.
Biosecurity and biosafety training. We provide customized biosecurity and biosafety training programs for security teams and for professional and support staff, tailored to your facilities, materials, operations and personnel. In addition, our specialists can assist in developing ongoing policies and procedures that meet applicable standards and guidelines.
With global experience, we understand the scientific, security, cultural and political issues that can affect the safety and operations of your facility.
Multi-disciplinary team. By combining doctoral-level microbiologists, biochemists and molecular biologists, along with leading authorities in threat assessment and vulnerability analysis, AT-RISK understands the biological organism at its pathological level and can build a biosecurity strategy around it.
Extensive experience. AT-RISK maintains the largest private collection of credentialed biosafety professionals and security experts in North America. Having worked in hundreds of labs around the world, over 30 years, the AT-RISK biosecurity team brings more authoritative solutions to labs and other facilities than any other group worldwide.
Global Security Operations Center (GSOC) and support. Staffed 24/7 by skilled analysts, GSOC collects data and tracks potential threats around the globe. AT-RISK can trace real-time threats that may affect operations, providing threat analysis and mitigation options at every project stage. These capabilities are extended by our close working relationships with government agencies involved in biosecurity and biosafety threat mitigation around the world.
- In 2014, several vials of freeze-dried smallpox virus were found in a remote section of an old lab. These forgotten samples were still viable.
- In 2007, research operations were suspended and funding was frozen for a federally funded university when workers were exposed to an animal pathogen. The lab also faced a Congressional investigation.
- A wave of anthrax (and hoax) attacks on several government and media targets in 2001 killed five people and sickened 17 others, and cost government and industry millions of dollars.
- More than 100 labs experimenting with dangerous biological agents have been cited by federal regulators since 2003, with total fines exceeding US$2.4 million.